QUTENZA Drug Patent Profile

When do Qutenza patents expire, and when can generic versions of Qutenza launch?

Qutenza is a drug marketed by Averitas and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-seven patent family members in twenty-seven countries.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the capsaicin profile page.

DrugPatentWatch^® Generic Entry Outlook for Qutenza

Qutenza was eligible for patent challenges on November 16, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 26, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for QUTENZA

International Patents:	67
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for QUTENZA

QUTENZA is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009		RX	Yes	Yes			Y
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009		RX	Yes	Yes			Y

International Patents for QUTENZA

See the table below for patents covering QUTENZA around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1539124
Japan	4279254
China	101601664	Therapeutic patch with polysiloxane matrix comprising capsaicin and method for preparing the same
Austria	240723
Japan	4943657
Brazil	PI0515270	sistema terapêutico transdérmico com uma camada adesiva, processo para siliconizar uma camada posterior do sistema e uso da camada posterior
Denmark	1791533

QUTENZA: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

QUTENZA (capsaicin patch 8%) is a prescription medical device indicated primarily for the management of neuropathic pain associated with postherpetic neuralgia (PHN) in adult patients. Since its FDA approval in 2009, QUTENZA has positioned itself within a niche market characterized by high treatment costs and unique delivery mechanisms. This report provides a comprehensive analysis of the current market landscape, investment outlook, and future revenue potential for QUTENZA, supported by recent industry data, market trends, and policy implications.

---

What Is the Investment Outlook for QUTENZA?

Market Validation and Revenue Performance

Parameter	Details
Initial Approval	FDA (2009), EMA (2010)
Global Sales (2022)	Estimated at $180 million globally (IQVIA)
Main Revenue Drivers	Postherpetic neuralgia, off-label uses for other neuropathic conditions
Orphan Drug Designation	No; indications are not classified as orphan, impacting market exclusivity

Key Revenue Drivers and Risks

• Market Penetration: Limited to specialized pain clinics; face competition from pharmacological alternatives such as gabapentinoids and antidepressants.
• Pricing Strategy: Premium pricing due to specialized device nature, with costs ranging from $700 to $1,000 per patch (~$1,600–$2,800 per treatment course).
• Market Expansion Potential: Off-label acceptance for diabetic neuropathy and other neuropathies remains limited but growing.
• Patent and Exclusivity: No active patents protecting QUTENZA exclusivity beyond 2023, increasing risk of biosimilar and generic competition.

Forecasted Revenue Trajectory (2023–2030)

Year	Estimated Global Sales	Comments
2023	$180 million	Stabilized, new payer negotiations ongoing
2025	$200–$250 million	Growth fueled by expanding use cases and markets
2030	$300–$350 million	Potential expansion in European markets; off-label adoption

---

Market Dynamics: Who Are the Key Stakeholders?

Competitive Landscape

Manufacturer	Product Name	Indication	Market Share (2022)	Comments
Heron Group	QUTENZA	Postherpetic neuralgia	~85%	Leader in capsaicin patch market
Teva	Generic capsaicin patches	Various off-label neuropathic uses	<10%	Growing off-label sales; potential biosimilar threat
Others	Compounded capsaicin patches	Off-label dermatological uses	<5%	Minimal market influence

Regulatory and Policy Influences

• Reimbursement Policies: Covered by most major payers in the U.S. and Europe, but reimbursement levels vary, impacting profitability.
• Medical Device Regulations: As a Class III device, QUTENZA requires rigorous post-marketing surveillance, which could influence market access.

Market Barriers and Opportunities

Barriers	Opportunities
Limited awareness among primary care physicians	Educational initiatives and clinical guidelines
High treatment costs	Demonstration of cost-effectiveness in health economics studies
Competition from oral medications	Potential for expanded indications in complex pain syndromes

---

Financial Trajectory and Investment Considerations

Cost Analysis and Profitability

Parameter	Estimate
Manufacturing Cost per Patch	~$150–$250
Average Selling Price	$700–$1,000 per patch
Gross Margin	Approximately 70–80%, after manufacturing costs
Research & Development	Focused on new indications and delivery mechanisms (~$10–$20 million annually)

Investment Risks

• Patent Expiry and Biosimilar Entry: The absence of orphan exclusivity leaves room for biosimilars, threatening price erosion.
• Market Penetration Challenges: Slow adoption due to reimbursement hurdles and clinician familiarity.
• Regulatory Shifts: Changes in device classification or reimbursement policies could impact market access.

Opportunities for Growth

• Expansion into Chronic Neuropathic Conditions: Potential off-label applications.
• European Market Penetration: Strong presence with considerable unmet needs.
• Combination Therapies: Integrations with pharmacologic agents for enhanced pain management.

---

Comparative Analysis: QUTENZA Versus Alternatives

Parameter	QUTENZA	Pharmacologic Alternatives	Advantages	Limitations
Mechanism	Topical capsaicin patch	Oral gabapentin, pregabalin, antidepressants	Targeted, localized therapy	Higher upfront cost, limited indication breadth
Onset of Relief	Immediate to days	1–2 weeks	Rapid relief	Longer-term efficacy variable
Side Effect Profile	Localized burning, erythema	Dizziness, sedation, systemic side effects	Favorable overall profile	Local skin reactions in some patients
Reimbursement and Cost	Premium, device-based	Lower cost, OTC options for some conditions	Premium pricing potential	Payer hesitancy, coverage limitations

---

Deep Dive: Key Market Segments and Future Trends

Primary Market: Postherpetic Neuralgia

• Market Size (2022): Approximately $300 million globally.
• Growth Rate: CAGR around 4.5% (2022–2027), driven by aging populations.
• Reimbursement Coverage: Most countries have policies; high out-of-pocket costs remain a barrier in some regions.

Off-Label and Adjacent Markets

Potential Indications	Market Size (Est.)	Regulatory Status	Growth Drivers
Diabetic Peripheral Neuropathy	$2 billion globally	Off-label; clinical trials ongoing	High unmet need; expanding physician awareness
Peripheral nerve injuries	Niche, smaller markets	Off-label; experimental	Opportunities for specialized applications

Future Market Trends

• Technological Innovation: Development of new capsaicin formulations and patch designs.
• Regulatory Pathways: Potential for FDA clearance of additional indications or device modifications.
• Market Access Strategies: Value-based pricing models and inclusion in pain management guidelines.

---

Key Takeaways

• Market Position: QUTENZA is a leader within a niche, high-cost, topical neuropathic pain market but faces imminent patent expiry and biosimilar threats.
• Revenue Potential: Anticipated steady growth to ~$350 million globally by 2030, fueled by expanded off-label use and European market penetration.
• Investment Risks: Patent expiration, reimbursement hurdles, and increasing competition from generic capsaicin patches and pharmacologic therapies.
• Growth Opportunities: Off-label expansion, device innovations, and regulatory approval for additional pain indications.
• Strategic Considerations: Investors must weigh high margins against patent volatility and evolving market dynamics, emphasizing diversification and R&D investments.

---

Frequently Asked Questions

1. What is the patent status of QUTENZA, and how does it impact future revenue?
   QUTENZA’s primary patents expired around 2023, exposing it to biosimilar competition. Future revenue hinges on continued clinical utility, off-label expansion, and new indication approvals.

2. How does reimbursement affect the commercial success of QUTENZA?
   Reimbursement policies vary by region but generally favor specialized device therapies. Challenges include high treatment costs and payer restrictions, influencing adoption rates.

3. What are the key competitors, and how does QUTENZA compare?
   Generic capsaicin patches and systemic pharmacological treatments compete for market share. QUTENZA’s advantages include localized control and potentially fewer systemic side effects.

4. What regulatory pathways could extend QUTENZA’s market life?
   Seeking approval for additional indications or device modifications, along with obtaining orphan or new drug exclusivities, could preserve market share.

5. What strategic moves should investors consider for QUTENZA?
   Monitoring patent landscapes, advocating for expanded indications, and investing in R&D initiatives for combination therapies can enhance long-term value.

---

References

1. [1] IQVIA, "Pharmaceutical Sales Data," 2022.
2. [2] FDA, "QUTENZA (capsaicin) prescribing information," 2009.
3. [3] European Medicines Agency, "Market authorization details for QUTENZA," 2010.
4. [4] MarketWatch, "Capsaicin Patch Market Analysis," 2023.
5. [5] Deloitte, "Pain Management Industry Outlook," 2022.